BioAtla (NASDAQ:BCAB) Trading Down 4.6% – Here’s Why

BioAtla, Inc. (NASDAQ:BCAB)’s share price was down 4.6% during mid-day trading on Friday . The stock traded as low as $3.30 and last traded at $3.33. Approximately 113,187 shares were traded during mid-day trading, an increase of 156% from the average daily volume of 44,150 shares. The stock had previously closed at $3.49.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on BCAB shares. Weiss Ratings reissued a “sell (e+)” rating on shares of BioAtla in a research note on Wednesday. Wall Street Zen raised BioAtla to a “hold” rating in a research note on Saturday, April 11th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $200.00.

BioAtla Stock Performance

The firm has a 50 day moving average of $4.75 and a 200-day moving average of $16.43. The stock has a market capitalization of $5.53 million, a PE ratio of -0.08 and a beta of 0.79.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Friday, May 15th. The company reported ($4.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.00) by $5.78.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC increased its position in BioAtla by 24.6% in the 1st quarter. ADAR1 Capital Management LLC now owns 228,107 shares of the company’s stock worth $37,000 after purchasing an additional 45,000 shares during the last quarter. Millennium Management LLC increased its position in BioAtla by 123.4% in the 4th quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock worth $433,000 after purchasing an additional 421,072 shares during the last quarter. Marshall Wace LLP acquired a new position in BioAtla in the 4th quarter worth about $508,000. Jane Street Group LLC increased its position in BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after purchasing an additional 123,597 shares during the last quarter. Finally, Susquehanna International Group LLP increased its position in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the last quarter. 77.23% of the stock is owned by institutional investors and hedge funds.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical?stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti?tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.